This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

I. Effects of Abrupt Discontinuation

Karl Rickels, MD; Edward Schweizer, MD; W. George Case, MD; David J. Greenblatt, MD

Arch Gen Psychiatry. 1990;47(10):899-907.

Abstract
• We compared the effect of abrupt discontinuation of therapeutic doses of short half-life and long half-life benzodiazepines in 57 benzodiazepine-dependent patients (daily use, >1 year). Despite the use of a mean daily dose of 14.1 mg of diazepam equivalents, there were notable residual symptoms of anxiety and depression present at intake (Hamilton Rating Scale for Anxiety score, 17.0: Hamilton Rating Scale for Depression score, 14.0). Benzodiazepine intake was stabilized for 3 weeks before double-blind assignment to placebo (n = 47), or continued benzodiazepine use (n = 10). Clinical assessments were performed daily, including benzodiazepine plasma levels. Depending on the outcome criteria used, anywhere from 58% to 100% of patients were judged to have experienced a withdrawal reaction, with a peak severity at 2 days for short half-life and 4 to 7 days for long half-life benzodiazepines. Relapse onto benzodiazepines occurred in 27% of patients who were receiving long half-life benzodiazepines and in 57% of patients who were receiving short halflife benzodiazepines. Baseline predictors of relapse were nonpanic diagnoses, a higher benzodiazepine dose, and a higher Eysenck neuroticism score. A short half-life and higher daily doses were associated with greater withdrawal severity, as were personality traits, such as dependency and neuroticism, less education and higher baseline levels of anxious and depressive symptoms. Patients who were able to remain free of benzodiazepines for at least 5 weeks obtained lower levels of anxiety than before benzodiazepine discontinuation. These results provide a detailed picture of the symptoms, time course, and multidimensional determinants of the benzodiazepine withdrawal syndrome.

Author Affiliations
From the Psychopharmacology Research Unit, Department of Psychiatry, University of Pennsylvania, Philadelphia (Drs Rickels, Schweizer, and Case), and the Division of Clinical Pharmacology, Departments of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, Mass (Dr Greenblatt).

Footnotes
Accepted for publication November 29, 1989.

Presented in part at the Session on New Research at the Annual Meeting of the American Psychiatric Association, Chicago, Ill, May 12, 1987.

Reprint requests to 203 Piersol Bldg, University Hospital, 3400 Spruce St, Philadelphia, PA 19104 (Dr Rickels).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Brief Intervention for Anxiety in Primary Care Patients
Roy-Byrne et al.
J Am Board Fam Med 2009;22:175-186.
ABSTRACT | FULL TEXT  

Benzodiazepine Use and Expenditures for Medicare Beneficiaries and the Implications of Medicare Part D Exclusions
Yang et al.
Psychiatr. Serv. 2008;59:384-391.
ABSTRACT | FULL TEXT  

Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar et al.
Br. J. Psychiatry 2006;189:213-220.
ABSTRACT | FULL TEXT  

Predictors of discontinuation of benzodiazepine prescription after sending a letter to long-term benzodiazepine users in family practice
Gorgels et al.
Fam Pract 2006;23:65-72.
ABSTRACT | FULL TEXT  

Pregabalin: A New Neuromodulator with Broad Therapeutic Indications
Shneker and McAuley
The Annals of Pharmacotherapy 2005;39:2029-2037.
ABSTRACT | FULL TEXT  

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
Baldwin et al.
J Psychopharmacol 2005;19:567-596.
ABSTRACT  

Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam
Rickels et al.
Arch Gen Psychiatry 2005;62:1022-1030.
ABSTRACT | FULL TEXT  

Postoperative Confusion Increases in Elderly Long-Term Benzodiazepine Users
Kudoh et al.
Anesth. Analg. 2004;99:1674-1678.
ABSTRACT | FULL TEXT  

The Dependent Personality Questionnaire (DPQ): A Screening Instrument for Dependent Personality
Tyrer et al.
Int J Soc Psychiatry 2004;50:10-17.
ABSTRACT  

Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial
Baillargeon et al.
CMAJ 2003;169:1015-1020.
ABSTRACT | FULL TEXT  

Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Pande et al.
Am. J. Psychiatry 2003;160:533-540.
ABSTRACT | FULL TEXT  

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study
ALLGULANDER et al.
Br. J. Psychiatry 2001;179:15-22.
ABSTRACT | FULL TEXT  

Imipramine and Buspirone in Treatment of Patients With Generalized Anxiety Disorder Who Are Discontinuing Long-Term Benzodiazepine Therapy
Rickels et al.
Am. J. Psychiatry 2000;157:1973-1979.
ABSTRACT | FULL TEXT  

Zolpidem Physical Dependence Assessed Across Increasing Doses Under a Once-Daily Dosing Regimen in Baboons
Weerts et al.
J. Pharmacol. Exp. Ther. 1998;285:41-53.
ABSTRACT | FULL TEXT  

Alprazolam withdrawal symptoms in agoraphobia with panic disorder: observations from a controlled Anglo-Canadian study
O'Sullivan et al.
J Psychopharmacol 1996;10:101-109.
ABSTRACT  

Use of Benzodiazepines in Anxiety Disorders
Shader and Greenblatt
NEJM 1993;328:1398-1405.
FULL TEXT  

Maintenance Drug Treatment of Panic Disorder: I. Results of a Prospective, Placebo-Controlled Comparison of Alprazolam and Imipramine
Schweizer et al.
Arch Gen Psychiatry 1993;50:51-60.
ABSTRACT  

Maintenance Drug Treatment for Panic Disorder: II. Short- and Long-term Outcome After Drug Taper
Rickels et al.
Arch Gen Psychiatry 1993;50:61-68.
ABSTRACT  

A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal
Lader and Morton
J Psychopharmacol 1992;6:357-363.
ABSTRACT  

Carbamazepine Treatment in Patients Discontinuing Long-term Benzodiazepine Therapy: Effects on Withdrawal Severity and Outcome
Schweizer et al.
Arch Gen Psychiatry 1991;48:448-452.
ABSTRACT  

Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer et al.
Arch Gen Psychiatry 1990;47:908-915.
ABSTRACT